Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study

Kalligeros, Markos; Shehadeh, Fadi; Atalla, Eleftheria; Mylona, Evangelia K.; Aung, Su; Pandita, Aakriti; Larkin, Jerry; Sanchez, Martha; Touzard-Romo, Francine; Brotherton, Amy; Shah, Rajeev; Cunha, Cheston B.

doi:10.1016/j.jgar.2020.07.018

Cited by 17 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, patients who received HCQ would be expected to require a longer stay. Indeed, when these factors were adjusted for in the analysis, the difference was non-significant, which is consistent with other reported data (41). These findings were also reported in a randomized clinical trial conducted in china on 150 COVID19 patients.…”

Section: Discussionsupporting

confidence: 91%

The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort

Abdulrahman

AlSayed

AlMadhi

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundHydroxychloroquine is an antimalarial drug that received worldwide news and media attention in the treatment of COVID-19 patients. This drug was used based on its antimicrobial and antiviral properties despite lack of definite evidence of clinical efficacy. In this study, we aim to assess the efficacy and safety of using Hydroxychloroquine in treatment of COVID-19 patients who are admitted in acute care hospitals in Bahrain.MethodologyWe conducted retrospective cohort study on a random sample of admitted COVID19 patients between 24 February and 31 July 2020. The study was conducted in four acute care COVID19 hospitals in Bahrain. Data was extracted from the medical records. The primary endpoint was the requirement of non-invasive ventilation, intubation or death. Secondary endpoint was length of hospitalization for survivors. Three methods of analysis were used to control for confounding factors: logistic multivariate regression, propensity score adjusted regression and matched propensity score analysis.ResultsA random sample of 1571 patients were included, 440 of which received HCQ (treatment group) and 1131 did not receive it (control group). Our results showed that HCQ did not have a significant effect on primary outcomes due to COVID-19 infection when compared to controls after adjusting for confounders (OR 1.43 95% CI 0.85 to 2.37, P value=0.17). Co-administration of azithromycin had no effect on primary outcomes (OR 2.7 95% CI 0.82 to 8.85 P value =0.10). HCQ was found to be associated with increased risk of hypoglycemia (OR 10.9 95% CI 1.72 - 69.49, P value =0.011) and diarrhea(OR 2.8, 95% CI 1.4-5.5, P value =0.003), but not QT prolongation(OR=1.92, 95% CI 0.95-3.9, P value =0.06) or cardiac arrhythmia.(OR=1.06, 95% CI 0.55-2.05, P value =0.85).ConclusionOur results showed no significant beneficial effect of using hydroxychloroquine on the outcome of COVID-19 patients. Moreover, the risk of hypoglycemia due to hydroxychloroquine would possess a significant risk for out of hospital use.

show abstract

Section: Discussionsupporting

confidence: 91%

The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort

Abdulrahman

AlSayed

AlMadhi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Hence, patients who received HCQ would be expected to require a longer stay. Indeed, when these factors were adjusted for in the analysis, the difference was non-significant, which is consistent with other reported data [ 43 ]. These findings were also reported in a randomized clinical trial conducted in China on 150 patients with COVID-19.…”

Section: Discussionsupporting

confidence: 91%

The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort

et al. 2021

View full text Add to dashboard Cite

“…Observational studies have shown that HCQ monotherapy or HCQ + AZM combination therapy might reduce mortality due to COVID-19 or promote clinical improvement [ 43 55 56 57 58 ] and that co-administration of HCQ and steroids could reduce the risk of hospitalization by 50–60% among those who were in the early stages of COVID-19 and not yet been hospitalized [ 59 ]. However, other studies have shown that these treatments did not reduce the mortality rate and worsened arrhythmia [ 32 40 41 42 60 61 62 63 64 65 ]. Some studies have shown that HCQ [ 34 ] and combination therapy with HCQ + AZM could help reduce the time to viral negativity [ 36 38 ].…”

Section: Resultsmentioning

confidence: 99%

Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19

et al. 2021

View full text Add to dashboard Cite

Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.

show abstract

Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study

Cited by 17 publications

References 5 publications

The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort

The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort

The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort

Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19

Contact Info

Product

Resources

About